18-Year-Old Becomes First Person Ever Cured of Rare Immune Disease Through Gene Editing

'It is really crazy to think about,' says 18-year-old Ty Sperle. 'We're definitely at a turning point in medicine.' Sperle, a UBC Okanagan student from Kelowna, British Columbia, has become the first person in the world to be cured of chronic granulomatous disease (CGD) — a rare genetic condition that cripples the immune system — through gene editing therapy. The results, published in the New England Journal of Medicine this week, mark a historic milestone for both CGD patients and the broader field of gene therapy. CGD affects the white blood cells responsible for fighting bacterial and fungal infections. People with the condition live under constant threat — ordinary infections that healthy immune systems shrug off can become life-threatening. Sperle was diagnosed at age five and spent his childhood managing the disease with a daily regime of pills, dealing with recurring canker sores, and living with the ever-present fear of infection. The treatment used a clinical gene editing approach to correct the genetic defect in Sperle's own cells. Rather than replacing the entire immune system through a bone marrow transplant (the previous standard treatment, which carries significant risks), the therapy precisely edited the faulty gene responsible for CGD. The results were remarkable. Sperle's immune function was restored. The canker sores stopped. The daily medications were no longer needed. For the first time in his life, his immune system works the way it should. 'I feel pretty similar to before,' Sperle said with characteristic understatement — a response that perhaps says more about his resilience than anything else. Being listed as 'Participant 1' in a landmark medical paper hasn't significantly altered his day-to-day life as a university student. But the implications extend far beyond one patient. CGD affects approximately 1 in 200,000 people worldwide. Until now, the only potential cure was a bone marrow transplant, which requires a matched donor and carries serious risks including graft-versus-host disease. Many patients simply manage the condition with lifelong medication. This gene editing approach could change that entirely — offering a precise, targeted cure without the risks of full immune system replacement. More broadly, the success adds to a growing body of evidence that gene editing therapies are moving from experimental promise to clinical reality. Each successful treatment builds the foundation for tackling other genetic diseases. In Kelowna, an 18-year-old goes about his university life — studying, socialising, being ordinary. And that ordinariness is the miracle. For the first time, Ty Sperle is living without CGD. And somewhere in a lab, scientists are already thinking about who might be Participant 2. 🧬